Indeed, pharmacologic inhibition of ATR, AKT, mTORC1 or downregulation of CBP20 expression (a factor initiating PRT [64]) significantly abrogated HLA-E upregulation in MM cells treated with CX-5461 (Fig. 6 and Supplementary Fig. 12). The gene discussed is AKT1; the disease is Miyoshi myopathy.